LAS VEGAS--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell ...

Homogeneous molecular catalysts are highly active and selective as they possess well-tailored structures and accessible sites. Unfortunately, the difficulty related to catalyst recovery impedes their ...

On March 26, 1954, National Cash Register sold its first roll of carbonless paper. Developed in collaboration with Appleton Coated Paper, the product harnessed brand-new microencapsulation technology ...

Encapsulating human stem-cell-derived beta cells in microcapsules made with a protein that repels key immune cells restored glucose metabolism in diabetic mice and protected the cells from immune ...

Innovations in hard-capsule technology enhance the flexibility that hard capsules can provide for dosage forms. The pharmaceutical industry is at the forefront of innovation, helping people to live ...

With the aim of restoring female hormone cycles for pediatric cancer survivors, a team of University of Michigan researchers ...

API-in-capsule approaches enable pharmaceutical companies to quickly assess new drug candidates with reduced API consumption and to increase speed to clinic. Pharmaceutical companies are faced with ...

PharmaCyte’s Chief Executive Officer, Kenneth L. Waggoner, said, “We have completed another study that proves exactly what we expected to find in the data. Like previous biocompatibility studies on ...